Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.
A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab compared to Mepolizumab in the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in patients receiving Standard of Care Therapy A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...